Northwest: FDA hasn't agreed main endpoint for DCVax trial

|About: Northwest Biotherapeutics... (NWBO)|By:, SA News Editor

The Street's Adam Feuerstein, who's having a bit of a running battle with Northwest Biotherapeutics (NWBO), digs deep into the company's 10-K annual report and finds that it hasn't agreed on a main target with the FDA for the Phase III trial of its brain-cancer vaccine DCVax.

Northwest wants the primary endpoint to be progression-free survival, but two other companies - ImmunoCellular Therapeutics and Celldex Therapeutics - have been using overall survival as the main goals of their trials for brain-cancer vaccines.

Northwest's shares are -3.1%.